Clinical trialNCT00131274CompletedPhase 2/PHASE3Interventional

Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study

SponsorDaniels, Craig E., M.D.Enrollment120Idiopathic Pulmonary FibrosisLung DiseasePulmonary Fibrosis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of the study is to evaluate the safety and efficacy of Gleevec (imatinib mesylate) in the treatment of idiopathic pulmonary fibrosis (IPF).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Craig E Daniels, MD
Mayo Clinic
Principal Investigator
clinicaltrials.gov ↗
Joseph Lasky, MD
Tulane University
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Imatinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Apr 2003
Primary completion: —
Completion: 31 Aug 2007
Last update posted: 5 Oct 2005
Registered enrollment: 120
Registry id: NCT00131274

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.